Neuropathology, biochemistry, and biophysics of α-synuclein aggregation

Journal of Neurochemistry

Volumn 103, Issue 1, 2007, Pages 17-37

  Uversky, Vladimir N ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE FOR BIOLOGICAL INSTRUMENTATION   (Russian Federation)

Author keywords

synuclein; Aggregation; Fibril; Natively unfolded protein; Neurodegeneration; Synucleinopathies

Indexed keywords

5 [4 (4 CHLOROBENZOYL) 1 PIPERAZINYL] 8 NITROQUINOLINE; ALPHA SYNUCLEIN; ANION; BAICALEIN; DOPAMINE; HERBICIDE; HISTONE; LEVODOPA; LIPID; METAL ION; METHIONINE; NEUROTOXIN; ORGANIC SOLVENT; PESTICIDE; POLYANION; POLYCATION; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; QUINOLINE DERIVATIVE; RIFAMPICIN; SODIUM CHLORIDE; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; CELL DEATH; DIMERIZATION; ENVIRONMENTAL FACTOR; HUMAN; IN VITRO STUDY; MEMBRANE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPROTECTION; NITRATION; NONHUMAN; OLIGOMERIZATION; OXIDATION; PARKINSON DISEASE; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEFECT; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; SYNUCLEINOPATHY;

ALPHA-SYNUCLEIN; ANIMALS; CELL DEATH; HUMANS; LEWY BODIES; NEURODEGENERATIVE DISEASES; PROTEIN CONFORMATION; PROTEIN FOLDING;

EID: 34548620297     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.04764.x     Document Type: Review

References (301)

1. Abou-Sleiman P. M., Muqit M. M. Wood N. W. (2006) Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7, 207 219.
2. Alim M. A., Hossain M. S., Arima K., Takeda K., Izumiyama Y., Nakamura M., Kaji H., Shinoda T., Hisanaga S. Ueda K. (2002) Tubulin seeds alpha-synuclein fibril formation. J. Biol. Chem. 277, 2112 2117.
3. Altschuler E. (1999) Aluminum-containing antacids as a cause of idiopathic Parkinson's disease. Med. Hypotheses 53, 22 23.
4. Arawaka S., Saito Y., Murayama S. Mori H. (1998) Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology 51, 887 889.
5. Arima K., Ueda K., Sunohara N., Hirai S., Izumiyama Y., Tonozuka-Uehara H. Kawai M. (1998a) Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res. 808, 93 100.
6. Arima K., Ueda K., Sunohara N., Arakawa K., Hirai S., Nakamura M., Tonozuka-Uehara H. Kawai M. (1998b) NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol. (Berl.) 96, 439 444.
7. Auluck P. K. Bonini N. M. (2002) Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med. 8, 1185 1186.
8. Auluck P. K., Chan H. Y., Trojanowski J. Q., Lee V. M. Bonini N. M. (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865 868.
9. Baba M., Nakajo S., Tu P. H., Tomita T., Nakaya K., Lee V. M., Trojanowski J. Q. Iwatsubo T. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879 884.
10. Bayer T. A., Jakala P., Hartmann T., Havas L., McLean C., Culvenor J. G., Li Q. X., Masters C. L., Falkai P. Beyreuther K. (1999) Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores. Neurosci. Lett. 266, 213 216.
11. Beal M. F. (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38, 357 366.
12. Bennett M. C. (2005) The role of alpha-synuclein in neurodegenerative diseases. Pharmacol. Ther. 105, 311 331.
13. Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V. Greenamyre J. T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301 1306.
14. Beyer K. (2006) Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. (Berl.) 112, 237 251.
15. Binolfi A., Rasia R. M., Bertoncini C. W., Ceolin M., Zweckstetter M., Griesinger C., Jovin T. M. Fernandez C. O. (2006) Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J. Am. Chem. Soc. 128, 9893 9901.
16. Bismuto E., Martelli P. L., De Maio A., Mita D. G., Irace G. Casadio R. (2002) Effect of molecular confinement on internal enzyme dynamics: frequency domain fluorometry and molecular dynamics simulation studies. Biopolymers 67, 85 95.
17. Bodles A. M., Guthrie D. J., Harriott P., Campbell P. Irvine G. B. (2000) Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils. Eur. J. Biochem. 267, 2186 2194.
18. Bodles A. M., Guthrie D. J., Greer B. Irvine G. B. (2001) Identification of the region of non-Abeta component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity. J. Neurochem. 78, 384 395.
19. Bodner R. A., Housman D. E. Kazantsev A. G. (2006a) New directions for neurodegenerative disease therapy: using chemical compounds to boost the formation of mutant protein inclusions. Cell Cycle 5, 1477 1480.
20. Bodner R. A., Outeiro T. F., Altmann S., Maxwell M. M., Cho S. H., Hyman B. T., McLean P. J., Young A. B., Housman D. E. Kazantsev A. G. (2006b) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc. Natl Acad. Sci. USA 103, 4246 4251.
21. Bonini N. M. Giasson B. I. (2005) Snaring the function of alpha-synuclein. Cell 123, 359 361.
22. Braak H., Braak E., Yilmazer D., de Vos R. A., Jansen E. N., Bohl J. Jellinger K. (1994) Amygdala pathology in Parkinson's disease. Acta Neuropathol. (Berl.) 88, 493 500.
23. Braak H., Sandmann-Keil D., Gai W. Braak E. (1999) Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neurosci. Lett. 265, 67 69.
24. Bracken C., Iakoucheva L. M., Romero P. R. Dunker A. K. (2004) Combining prediction, computation and experiment for the characterization of protein disorder. Curr. Opin. Struct. Biol. 14, 570 576.
25. Bussell R. Jr. Eliezer D. (2001) Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein. J. Biol. Chem. 276, 45996 46003.
26. Butterfield D. A. Kanski J. (2001) Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Ageing Dev. 122, 945 962.
27. Cappai R., Leck S. L., Tew D. J. et al. (2005) Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J. 19, 1377 1379.
28. Castagnet P. I., Golovko M. Y., Barcelo-Coblijn G. C., Nussbaum R. L. Murphy E. J. (2005) Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice. J. Neurochem. 94, 839 849.
29. Chandra S., Chen X., Rizo J., Jahn R. Sudhof T. C. (2003) A broken alpha-helix in folded alpha-synuclein. J. Biol. Chem. 278, 15313 15318.
30. Chandra S., Gallardo G., Fernandez-Chacon R., Schluter O. M. Sudhof T. C. (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123, 383 396.
31. Chen Y. G., Siddhanta A., Austin C. D., Hammond S. M., Sung T. C., Frohman M. A., Morris A. J. Shields D. (1997) Phospholipase D stimulates release of nascent secretory vesicles from the trans-Golgi network. J. Cell Biol. 138, 495 504.
32. Clayton D. F. George J. M. (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21, 249 254.
33. Clayton D. F. George J. M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120 129.
34. Cohlberg J. A., Li J., Uversky V. N. Fink A. L. (2002) Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry 41, 1502 1511.
35. Cole N. B., Murphy D. D., Grider T., Rueter S., Brasaemle D. Nussbaum R. L. (2002) Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J. Biol. Chem. 277, 6344 6352.
36. Conway K. A., Harper J. D. Lansbury P. T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318 1320.
37. Conway K. A., Harper J. D. Lansbury P. T. Jr. (2000a) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552 2563.
38. Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E. Lansbury P. T. Jr. (2000b) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571 576.
39. Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Harper J. D., Williamson R. E. Lansbury P. T. Jr. (2000c) Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann. NY Acad. Sci. 920, 42 45.
40. Conway K. A., Rochet J. C., Bieganski R. M. Lansbury P. T. Jr. (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346 1349.
41. Cookson M. R. (2005) The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74, 29 52.
42. Cookson M. R. (2006) Hero versus antihero: the multiple roles of alpha-synuclein in neurodegeneration. Exp. Neurol. 199, 238 242.
43. Cooper A. A., Gitler A. D., Cashikar A. et al. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313, 324 328.
44. Crowther R. A., Jakes R., Spillantini M. G. Goedert M. (1998) Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 436, 309 312.
45. Crowther R. A., Daniel S. E. Goedert M. (2000) Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain. Neurosci. Lett. 292, 128 130.
46. Dauer W. Przedborski S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889 909.
47. Daughdrill G. W., Pielak G. J., Uversky V. N., Cortese M. S. Dunker A. K. (2005) Natively disordered proteins, in Handbook of Protein Folding (Buchner J. Kiefhaber T., eds pp. 271 353. Wiley-VCH, Verlag GmbH & Co. KGaA, Weinheim, Germany.
48. Davidson W. S., Jonas A., Clayton D. F. George J. M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443 9449.
49. Davis L. E. Adair J. C. (1999) Parkinsonism from methanol poisoning: benefit from treatment with anti-Parkinson drugs. Mov. Disord. 14, 520 522.
50. Dev K. K., Hofele K., Barbieri S., Buchman V. L. van der Putten H. (2003) Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45, 14 44.
51. Di Monte D. A. (2001) The role of environmental agents in Parkinson's disease. Clin. Neurosci. Res. 1, 419 426.
52. Di Monte D. A. (2003) The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2, 531 538.
53. Di Monte D. A., Lavasani M. Manning-Bog A. B. (2002) Environmental factors in Parkinson's disease. Neurotoxicology 23, 487 502.
54. Dickson D. W., Ruan D., Crystal H., Mark M. H., Davies P., Kress Y. Yen S. H. (1991) Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology 41, 1402 1409.
55. Ding T. T., Lee S. J., Rochet J. C. Lansbury P. T. Jr. (2002) Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41, 10209 10217.
56. Dosztanyi Z., Csizmok V., Tompa P. Simon I. (2005) IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics 21, 3433 3434.
57. Duda J. E., Giasson B. I., Chen Q., Gur T. L., Hurtig H. I., Stern M. B., Gollomp S. M., Ischiropoulos H., Lee V. M. Trojanowski J. Q. (2000) Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am. J. Pathol. 157, 1439 1445.
58. Dunker A. K. Obradovic Z. (2001) The protein trinity-linking function and disorder. Nat. Biotechnol. 19, 805 806.
59. Dunker A. K., Lawson J. D., Brown C. J. et al. (2001) Intrinsically disordered protein. J. Mol. Graph. Model 19, 26 59.
60. Dunker A. K., Brown C. J. Obradovic Z. (2002a) Identification and functions of usefully disordered proteins. Adv. Protein Chem. 62, 25 49.
61. Dunker A. K., Brown C. J., Lawson J. D., Iakoucheva L. M. Obradovic Z. (2002b) Intrinsic disorder and protein function. Biochemistry 41, 6573 6582.
62. Dunker A. K., Cortese M. S., Romero P., Iakoucheva L. M. Uversky V. N. (2005) Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J. 272, 5129 5148.
63. Dyson H. J. Wright P. E. (2005) Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 6, 197 208.
64. Eggers D. K. Valentine J. S. (2001a) Crowding and hydration effects on protein conformation: a study with sol-gel encapsulated proteins. J. Mol. Biol. 314, 911 922.
65. Eggers D. K. Valentine J. S. (2001b) Molecular confinement influences protein structure and enhances thermal protein stability. Protein Sci. 10, 250 261.
66. El-Agnaf O. M., Jakes R., Curran M. D. Wallace A. (1998a) Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett. 440, 67 70.
67. El-Agnaf O. M., Bodles A. M., Guthrie D. J., Harriott P. Irvine G. B. (1998b) The N-terminal region of non-A beta component of Alzheimer's disease amyloid is responsible for its tendency to assume beta-sheet and aggregate to form fibrils. Eur. J. Biochem. 258, 157 163.
68. El-Agnaf O. M., Jakes R., Curran M. D., Middleton D., Ingenito R., Bianchi E., Pessi A., Neill D. Wallace A. (1998c) Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 440, 71 75.
69. Eliezer D., Kutluay E., Bussell R. Jr. Browne G. (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 1061 1073.
70. Ellis R. J. (2001) Macromolecular crowding: obvious but underappreciated. Trends Biochem. Sci. 26, 597 604.
71. Eriksen J. L., Wszolek Z. Petrucelli L. (2005) Molecular pathogenesis of Parkinson disease. Arch. Neurol. 62, 353 357.
72. Fall P. A., Fredrikson M., Axelson O. Granerus A. K. (1999) Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov. Disord. 14, 28 37.
73. Farrer M., Kachergus J., Forno L. et al. (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55, 174 179.
74. Fink A. L. (2005) Natively unfolded proteins. Curr. Opin. Struct. Biol. 15, 35 41.
75. Forno L. S. (1996) Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55, 259 272.
76. Fortin D. L., Troyer M. D., Nakamura K., Kubo S., Anthony M. D. Edwards R. H. (2004) Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 24, 6715 6723.
77. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M. S., Shen J., Takio K. Iwatsubo T. (2002) Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160 164.
78. Fulton A. B. (1982) How crowded is the cytoplasm? Cell 30, 345 347.
79. Furesz S. (1970) Chemical and biological properties of rifampicin. Antibiot. Chemother. 16, 316 351.
80. Gai W. P., Power J. H., Blumbergs P. C. Blessing W. W. (1998) Multiple-system atrophy: a new alpha-synuclein disease? Lancet 352, 547 548.
81. Gai W. P., Power J. H., Blumbergs P. C., Culvenor J. G. Jensen P. H. (1999) Alpha-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components. J. Neurochem. 73, 2093 2100.
82. Galat A. (2003) Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity-targets-functions. Curr. Top. Med. Chem. 3, 1315 1347.
83. Galpern W. R. Lang A. E. (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann. Neurol. 59, 449 458.
84. Galvin J. E., Lee V. M., Schmidt M. L., Tu P. H., Iwatsubo T. Trojanowski J. Q. (1999) Pathobiology of the Lewy body. Adv. Neurol. 80, 313 324.
85. Galvin J. E., Lee V. M. Trojanowski J. Q. (2001) Synucleinopathies: clinical and pathological implications. Arch. Neurol. 58, 186 190.
86. Gandhi S. Wood N. W. (2005) Molecular pathogenesis of Parkinson's disease. Hum. Mol. Genet. 14 Spec No. 2, 2749 2755.
87. Gao Z., Huang K. Xu H. (2001) Protective effects of flavonoids in the roots of Scutellaria baicalensis Georgi against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells. Pharmacol. Res. 43, 173 178.
88. George J. M., Jin H., Woods W. S. Clayton D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361 372.
89. Gerard M., Debyser Z., Desender L., Kahle P. J., Baert J., Baekelandt V. Engelborghs Y. (2006) The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy. FASEB J. 20, 524 526.
90. Giasson B. I., Uryu K., Trojanowski J. Q. Lee V. M. (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619 7622.
91. Giasson B. I., Duda J. E., Murray I. V., Chen Q., Souza J. M., Hurtig H. I., Ischiropoulos H., Trojanowski J. Q. Lee V. M. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985 989.
92. Giasson B. I., Duda J. E., Quinn S. M., Zhang B., Trojanowski J. Q. Lee V. M. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34, 521 533.
93. Glaser C. B., Yamin G., Uversky V. N. Fink A. L. (2005) Methionine oxidation, alpha-synuclein and Parkinson's disease. Biochim. Biophys. Acta 1703, 157 169.
94. Goedert M. (1999) Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 1101 1118.
95. Goedert M. (2001) Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492 501.
96. Goers J., Uversky V. N. Fink A. L. (2003a) Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro. Protein Sci. 12, 702 707.
97. Goers J., Manning-Bog A. B., McCormack A. L., Millett I. S., Doniach S., Di Monte D. A., Uversky V. N. Fink A. L. (2003b) Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 42, 8465 8471.
98. Goldberg M. S. Lansbury P. T. Jr. (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. 2, E115 E119.
99. Golovko M. Y., Faergeman N. J., Cole N. B., Castagnet P. I., Nussbaum R. L. Murphy E. J. (2005) Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of alpha-synuclein palmitate binding. Biochemistry 44, 8251 8259.
100. Golts N., Snyder H., Frasier M., Theisler C., Choi P. Wolozin B. (2002) Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J. Biol. Chem. 277, 16116 16123.
101. Good P. F., Olanow C. W. Perl D. P. (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 593, 343 346.
102. Gorell J. M., Johnson C. C., Rybicki B. A., Peterson E. L. Richardson R. J. (1998) The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50, 1346 1350.
103. Gorell J. M., Rybicki B. A., Johnson C. C. Peterson E. L. (1999a) Occupational metal exposures and the risk of Parkinson's disease. Neuroepidemiology 18, 303 308.
104. Gorell J. M., Johnson C. C., Rybicki B. A., Peterson E. L., Kortsha G. X., Brown G. G. Richardson R. J. (1999b) Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 20, 239 247.
105. Gosavi N., Lee H. J., Lee J. S., Patel S. Lee S. J. (2002) Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 277, 48984 48992.
106. Greenbaum E. A., Graves C. L., Mishizen-Eberz A. J., Lupoli M. A., Lynch D. R., Englander S. W., Axelsen P. H. Giasson B. I. (2005) The E46 K mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem. 280, 7800 7807.
107. Hageman G., van der Hoek J., van Hout M., van der Laan G., Steur E. J., de Bruin W. Herholz K. (1999) Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure. J. Neurol. 246, 198 206.
108. Han H., Weinreb P. H. Lansbury P. T. Jr. (1995) The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem. Biol. 2, 163 169.
109. Hashimoto M., Rockenstein E., Mante M., Mallory M. Masliah E. (2001) Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32, 213 223.
110. Hernan M. A., Takkouche B., Caamano-Isorna F. Gestal-Otero J. J. (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 52, 276 284.
111. Hertzman C., Wiens M., Snow B., Kelly S. Calne D. (1994) A case-control study of Parkinson's disease in a horticultural region of British Columbia. Mov. Disord. 9, 69 75.
112. Hirsch E. C., Brandel J. P., Galle P., Javoy-Agid F. Agid Y. (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56, 446 451.
113. Ho G. J., Gregory E. J., Smirnova I. V., Zoubine M. N. Festoff B. W. (1994) Cross-linking of beta-amyloid protein precursor catalyzed by tissue transglutaminase. FEBS Lett. 349, 151 154.
114. Hokenson M. J., Uversky V. N., Goers J., Yamin G., Munishkina L. A. Fink A. L. (2004) Role of individual methionines in the fibrillation of methionine-oxidized alpha-synuclein. Biochemistry 43, 4621 4633.
115. Ikezoe T., Chen S. S., Heber D., Taguchi H. Koeffler H. P. (2001) Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate 49, 285 292.
116. Irizarry M. C., Growdon W., Gomez-Isla T., Newell K., George J. M., Clayton D. F. Hyman B. T. (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J. Neuropathol. Exp. Neurol. 57, 334 337.
117. Ischiropoulos H. (1998) Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. Arch. Biochem. Biophys. 356, 1 11.
118. Ischiropoulos H. (2003) Biological selectivity and functional aspects of protein tyrosine nitration. Biochem. Biophys. Res. Commun. 305, 776 783.
119. Iwai A., Yoshimoto M., Masliah E. Saitoh T. (1995a) Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 34, 10139 10145.
120. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H. A., Kittel A. Saitoh T. (1995b) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467 475.
121. Jao C. C., Der-Sarkissian A., Chen J. Langen R. (2004) Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc. Natl Acad. Sci. USA 101, 8331 8336.
122. Jellinger K. A. (2003) Neuropathological spectrum of synucleinopathies. Mov. Disord. 18 (Suppl. 6 S2 S12.
123. Jenco J. M., Rawlingson A., Daniels B. Morris A. J. (1998) Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 37, 4901 4909.
124. Jensen P. H., Nielsen M. S., Jakes R., Dotti C. G. Goedert M. (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273, 26292 26294.
125. Jin J., Li G. J., Davis J., Zhu D., Wang Y., Pan C. Zhang J. (2007) Identification of novel proteins interacting with both α-synuclein and DJ-1. Mol. Cell Proteomics 6, 845 859.
126. Jo E., McLaurin J., Yip C. M., St George-Hyslop P. Fraser P. E. (2000) Alpha-synuclein membrane interactions and lipid specificity. J. Biol. Chem. 275, 34328 34334.
127. Jo E., Darabie A. A., Han K., Tandon A., Fraser P. E. McLaurin J. (2004) Alpha-synuclein-synaptosomal membrane interactions: implications for fibrillogenesis. Eur. J. Biochem. 271, 3180 3189.
128. Junn E., Ronchetti R. D., Quezado M. M., Kim S. Y. Mouradian M. M. (2003) Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 100, 2047 2052.
129. Kahle P. J., Neumann M., Ozmen L. et al. (2002) Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep. 3, 583 588.
130. Kamp F. Beyer K. (2006) Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles. J. Biol. Chem. 281, 9251 9259.
131. Kim Y. S., Laurine E., Woods W. Lee S. J. (2006) A novel mechanism of interaction between alpha-synuclein and biological membranes. J. Mol. Biol. 360, 386 397.
132. Kisilevsky R. (2000) Review: amyloidogenesis-unquestioned answers and unanswered questions. J. Struct. Biol. 130, 99 108.
133. Klawans H. L., Stein R. W., Tanner C. M. Goetz C. G. (1982) A pure parkinsonian syndrome following acute carbon monoxide intoxication. Arch. Neurol. 39, 302 304.
134. Ko L., Mehta N. D., Farrer M., Easson C., Hussey J., Yen S., Hardy J. Yen S. H. (2000) Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. J. Neurochem. 75, 2546 2554.
135. Kowall N. W., Hantraye P., Brouillet E., Beal M. F., McKee A. C. Ferrante R. J. (2000) MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11, 211 213.
136. Krishnan S., Chi E. Y., Wood S. J. et al. (2003) Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry 42, 829 837.
137. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J. T., Schols L. Riess O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106 108.
138. Langston J. W. Ballard P. A. Jr. (1983) Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med. 309, 310.
139. Lansbury P. T. Jr. (1999) Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc. Natl Acad. Sci. USA 96, 3342 3344.
140. Larsen K. E., Schmitz Y., Troyer M. D. et al. (2006) Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci. 26, 11915 11922.
141. Lashuel H. A., Hartley D., Petre B. M., Walz T. Lansbury P. T. Jr. (2002a) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291.
142. Lashuel H. A., Petre B. M., Wall J., Simon M., Nowak R. J., Walz T. Lansbury P. T. Jr. (2002b) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089 1102.
143. de Laureto P. P., Tosatto L., Frare E., Marin O., Uversky V. N. Fontana A. (2006) Conformational properties of the SDS-bound state of alpha-synuclein probed by limited proteolysis: unexpected rigidity of the acidic C-terminal tail. Biochemistry 45, 11523 11531.
144. Lavedan C. (1998) The synuclein family. Genome Res. 8, 871 880.
145. Lee H. J., Choi C. Lee S. J. (2002) Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277, 671 678.
146. Lesort M., Chun W., Johnson G. V. Ferrante R. J. (1999) Tissue transglutaminase is increased in Huntington's disease brain. J. Neurochem. 73, 2018 2027.
147. Levine R. L., Mosoni L., Berlett B. S. Stadtman E. R. (1996) Methionine residues as endogenous antioxidants in proteins. Proc. Natl Acad. Sci. USA 93, 15036 15040.
148. Li X., Romero P., Rani M., Dunker A. K. Obradovic Z. (1999) Predicting protein disorder for N-, C-, and internal regions. Genome Inform. Ser Workshop Genome Inform. 10, 30 40.
149. Li B. Q., Fu T., Gong W. H., Dunlop N., Kung H., Yan Y., Kang J. Wang J. M. (2000) The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines. Immunopharmacology 49, 295 306.
150. Li J., Uversky V. N. Fink A. L. (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40, 11604 11613.
151. Li J., Uversky V. N. Fink A. L. (2002) Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. Neurotoxicology 23, 553 567.
152. Li J., Zhu M., Manning-Bog A. B., Di Monte D. A. Fink A. L. (2004a) Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J. 18, 962 964.
153. Li J., Zhu M., Rajamani S., Uversky V. N. Fink A. L. (2004b) Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem. Biol. 11, 1513 1521.
154. Lindersson E. Jensen P. H. (2004) Alpha-synuclein binding proteins, in Molecular Mechanisms of Parkinson's Disease (Kahle P. J. Haass C., eds pp. 1 12. Landes Bioscience, Georgetown.
155. Lindersson E. K., Hojrup P., Gai W. P., Locker D., Martin D. Jensen P. H. (2004) Alpha-synuclein filaments bind the transcriptional regulator HMGB-1. Neuroreport 15, 2735 2739.
156. Lindersson E., Lundvig D., Petersen C. et al. (2005) p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. J. Biol. Chem. 280, 5703 5715.
157. Liou H. H., Tsai M. C., Chen C. J., Jeng J. S., Chang Y. C., Chen S. Y. Chen R. C. (1997) Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 48, 1583 1588.
158. Litvan I., Halliday G., Hallett M. et al. (2007) The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J. Neuropathol. Exp. Neurol. 66, 251 257.
159. Liu I. H., Uversky V. N., Munishkina L. A., Fink A. L., Halfter W. Cole G. J. (2005) Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation. Glycobiology 15, 1320 1331.
160. Lo Bianco C., Ridet J. L., Schneider B. L., Deglon N. Aebischer P. (2002) Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl Acad. Sci. USA 99, 10813 10818.
161. Lowe R., Pountney D. L., Jensen P. H., Gai W. P. Voelcker N. H. (2004) Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci. 13, 3245 3252.
162. Lucking C. B. Brice A. (2000) Alpha-synuclein and Parkinson's disease. Cell Mol. Life Sci. 57, 1894 1908.
163. Lundvig D., Lindersson E. Jensen P. H. (2005) Pathogenic effects of alpha-synuclein aggregation. Brain Res. Mol. Brain Res. 134, 3 17.
164. Madine J., Doig A. J. Middleton D. A. (2006) A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. Biochemistry 45, 5783 5792.
165. Maguire-Zeiss K. A. Federoff H. J. (2003) Convergent pathobiologic model of Parkinson's disease. Ann. NY Acad. Sci. 991, 152 166.
166. Maguire-Zeiss K. A., Short D. W. Federoff H. J. (2005) Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease? Brain Res. Mol. Brain Res. 134, 18 23.
167. Manning-Bog A. B., McCormack A. L., Li J., Uversky V. N., Fink A. L. Di Monte D. A. (2002) The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277, 1641 1644.
168. Maroteaux L., Campanelli J. T. Scheller R. H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804 2815.
169. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A. Mucke L. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265 1269.
170. McCormack A. L., Thiruchelvam M., Manning-Bog A. B., Thiffault C., Langston J. W., Cory-Slechta D. A. Di Monte D. A. (2002) Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 10, 119 127.
171. McLaurin J., Yang D., Yip C. M. Fraser P. E. (2000) Review: modulating factors in amyloid-beta fibril formation. J. Struct. Biol. 130, 259 270.
172. McLean P. J., Kawamata H., Ribich S. Hyman B. T. (2000) Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J. Biol. Chem. 275, 8812 8816.
173. McLean P. J., Kawamata H., Shariff S., Hewett J., Sharma N., Ueda K., Breakefield X. O. Hyman B. T. (2002) TorsinA and heat shock proteins act as
174. McNulty B. C., Young G. B. Pielak G. J. (2006) Macromolecular crowding in the Escherichia coli periplasm maintains alpha-synuclein disorder. J. Mol. Biol. 355, 893 897.
175. Miller M. L. Johnson G. V. (1995) Transglutaminase cross-linking of the tau protein. J. Neurochem. 65, 1760 1770.
176. Miller D. W., Hague S. M., Clarimon J., Baptista M., Gwinn-Hardy K., Cookson M. R. Singleton A. B. (2004) Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62, 1835 1838.
177. Minton A. P. (2000a) Effect of a concentrated 'inert' macromolecular cosolute on the stability of a globular protein with respect to denaturation by heat and by chaotropes: a statistical-thermodynamic model. Biophys. J. 78, 101 109.
178. Minton A. P. (2000b) Implications of macromolecular crowding for protein assembly. Curr. Opin. Struct. Biol. 10, 34 39.
179. Minton A. P. (2001) The influence of macromolecular crowding and macromolecular confinement on biochemical reactions in physiological media. J. Biol. Chem. 276, 10577 10580.
180. Moore D. J., West A. B., Dawson V. L. Dawson T. M. (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57 87.
181. Morar A. S., Olteanu A., Young G. B. Pielak G. J. (2001) Solvent-induced collapse of alpha-synuclein and acid-denatured cytochrome c. Protein Sci. 10, 2195 2199.
182. Morris H. R. (2005) Genetics of Parkinson's disease. Ann. Med. 37, 86 96.
183. Moskovitz J., Jenkins N. A., Gilbert D. J., Copeland N. G., Jursky F., Weissbach H. Brot N. (1996) Chromosomal localization of the mammalian peptide-methionine sulfoxide reductase gene and its differential expression in various tissues. Proc. Natl Acad. Sci. USA 93, 3205 3208.
184. Mukaetova-Ladinska E. B. McKeith I. G. (2006) Pathophysiology of synuclein aggregation in Lewy body disease. Mech. Ageing Dev. 127, 188 202.
185. Munishkina L. A., Phelan C., Uversky V. N. Fink A. L. (2003) Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes. Biochemistry 42, 2720 2730.
186. Munishkina L. A., Henriques J., Uversky V. N. Fink A. L. (2004) Role of protein-water interactions and electrostatics in alpha-synuclein fibril formation. Biochemistry 43, 3289 3300.
187. Murray I. V., Giasson B. I., Quinn S. M., Koppaka V., Axelsen P. H., Ischiropoulos H., Trojanowski J. Q. Lee V. M. (2003) Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42, 8530 8540.
188. Narayanan V. Scarlata S. (2001) Membrane binding and self-association of alpha-synucleins. Biochemistry 40, 9927 9934.
189. Narhi L., Wood S. J., Steavenson S. et al. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274, 9843 9846.
190. Necula M., Chirita C. N. Kuret J. (2003) Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro. J. Biol. Chem. 278, 46674 46680.
191. Neumann M., Kahle P. J., Giasson B. I. et al. (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 110, 1429 1439.
192. Nielsen M. S., Vorum H., Lindersson E. Jensen P. H. (2001) Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization. J. Biol. Chem. 276, 22680 22684.
193. Nishie M., Mori F., Yoshimoto M., Takahashi H. Wakabayashi K. (2004a) A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy. Neuropathol. Appl. Neurobiol. 30, 546 554.
194. Nishie M., Mori F., Fujiwara H., Hasegawa M., Yoshimoto M., Iwatsubo T., Takahashi H. Wakabayashi K. (2004b) Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol. (Berl.) 107, 292 298.
195. Obradovic Z., Peng K., Vucetic S., Radivojac P. Dunker A. K. (2005) Exploiting heterogeneous sequence properties improves prediction of protein disorder. Proteins 61 (Suppl. 7 176 182.
196. Ohlson C. G. Hogstedt C. (1981) Parkinson's disease and occupational exposure to organic solvents, agricultural chemicals and mercury-a case-referent study. Scand. J. Work Environ. Health 7, 252 256.
197. Okazaki H., Lipkin L. E. Aronson S. M. (1961) Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J. Neuropathol. Exp. Neurol. 20, 237 244.
198. Okochi M., Walter J., Koyama A., Nakajo S., Baba M., Iwatsubo T., Meijer L., Kahle P. J. Haass C. (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 275, 390 397.
199. Outeiro T. F. Lindquist S. (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302, 1772 1775.
200. Paik S. R., Lee J. H., Kim D. H., Chang C. S. Kim J. (1997) Aluminum-induced structural alterations of the precursor of the non-A beta component of Alzheimer's disease amyloid. Arch. Biochem. Biophys. 344, 325 334.
201. Paik S. R., Shin H. J., Lee J. H., Chang C. S. Kim J. (1999) Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem. J. 340, 821 828.
202. Paik S. R., Shin H. J. Lee J. H. (2000) Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide. Arch. Biochem. Biophys. 378, 269 277.
203. Papp M. I., Kahn J. E. Lantos P. L. (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J. Neurol. Sci. 94, 79 100.
204. Paxinou E., Chen Q., Weisse M., Giasson B. I., Norris E. H., Rueter S. M., Trojanowski J. Q., Lee V. M. Ischiropoulos H. (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21, 8053 8061.
205. Perrin R. J., Woods W. S., Clayton D. F. George J. M. (2000) Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem. 275, 34393 34398.
206. Perrin R. J., Woods W. S., Clayton D. F. George J. M. (2001) Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J. Biol. Chem. 276, 41958 41962.
207. Pezzoli G., Strada O., Silani V. et al. (1996) Clinical and pathological features in hydrocarbon-induced parkinsonism. Ann. Neurol. 40, 922 925.
208. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045 2047.
209. Pountney D. L., Lowe R., Quilty M., Vickers J. C., Voelcker N. H. Gai W. P. (2004) Annular alpha-synuclein species from purified multiple system atrophy inclusions. J. Neurochem. 90, 502 512.
210. Pountney D. L., Treweek T. M., Chataway T., Huang Y., Chegini F., Blumbergs P. C., Raftery M. J. Gai W. P. (2005) Alpha B-crystallin is a major component of glial cytoplasmic inclusions in multiple system atrophy. Neurotox. Res. 7, 77 85.
211. Pronin A. N., Morris A. J., Surguchov A. Benovic J. L. (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275, 26515 26522.
212. van der Putten H., Wiederhold K. H., Probst A. et al. (2000) Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20, 6021 6029.
213. Ramakrishnan M., Jensen P. H. Marsh D. (2003) Alpha-synuclein association with phosphatidylglycerol probed by lipid spin labels. Biochemistry 42, 12919 12926.
214. Rekas A., Adda C. G., Andrew Aquilina J. et al. (2004) Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity. J. Mol. Biol. 340, 1167 1183.
215. Romero P., Obradovic Z., Li X., Garner E. C., Brown C. J. Dunker A. K. (2001) Sequence complexity of disordered protein. Proteins 42, 38 48.
216. Romero P., Obradovic Z. Dunker A. K. (2004) Natively disordered proteins:functions and predictions. Appl. Bioinformatics 3, 105 113.
217. Saito Y., Kawashima A., Ruberu N. N. et al. (2003) Accumulation of phosphorylated alpha-synuclein in aging human brain. J. Neuropathol. Exp. Neurol. 62, 644 654.
218. Scherzer C. R., Jensen R. V., Gullans S. R. Feany M. B. (2003) Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. Hum. Mol. Genet. 12, 2457 2466.
219. Seidler A., Hellenbrand W., Robra B. P., Vieregge P., Nischan P., Joerg J., Oertel W. H., Ulm G. Schneider E. (1996) Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 46, 1275 1284.
220. Selkoe D. J., Abraham C. Ihara Y. (1982) Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers. Proc. Natl Acad. Sci. USA 79, 6070 6074.
221. Semchuk K. M., Love E. J. Lee R. G. (1992) Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 42, 1328 1335.
222. Semchuk K. M., Love E. J. Lee R. G. (1993) Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 43, 1173 1180.
223. Serpell L. C., Berriman J., Jakes R., Goedert M. Crowther R. A. (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl Acad. Sci. USA 97, 4897 4902.
224. Sharon R., Bar-Joseph I., Mirick G. E., Serhan C. N. Selkoe D. J. (2003a) Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J. Biol. Chem. 278, 49874 49881.
225. Sharon R., Bar-Joseph I., Frosch M. P., Walsh D. M., Hamilton J. A. Selkoe D. J. (2003b) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583 595.
226. Shashidharan P., Kramer B. C., Walker R. H., Olanow C. W. Brin M. F. (2000a) Immunohistochemical localization and distribution of torsinA in normal human and rat brain. Brain Res. 853, 197 206.
227. Shashidharan P., Good P. F., Hsu A., Perl D. P., Brin M. F. Olanow C. W. (2000b) TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease. Brain Res. 877, 379 381.
228. Sherer T. B., Kim J. H., Betarbet R. Greenamyre J. T. (2003) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179, 9 16.
229. Shieh D. E., Liu L. T. Lin C. C. (2000) Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Res. 20, 2861 2865.
230. Shtilerman M. D., Ding T. T. Lansbury P. T. Jr. (2002) Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry 41, 3855 3860.
231. Singleton A. B., Farrer M., Johnson J. et al. (2003) Alpha-synuclein locus triplication causes Parkinson's disease. Science 302, 841.
232. Singleton A., Gwinn-Hardy K., Sharabi Y., Li S. T., Holmes C., Dendi R., Hardy J., Crawley A. Goldstein D. S. (2004) Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain 127, 768 772.
233. Souza J. M., Giasson B. I., Chen Q., Lee V. M. Ischiropoulos H. (2000) Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275, 18344 18349.
234. Spillantini M. G. Goedert M. (2000) The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. NY Acad. Sci. 920, 16 27.
235. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839 840.
236. Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M. Goedert M. (1998a) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469 6473.
237. Spillantini M. G., Crowther R. A., Jakes R., Cairns N. J., Lantos P. L. Goedert M. (1998b) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205 208.
238. Stadtman E. R. (1993) Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu. Rev. Biochem. 62, 797 821.
239. Sun H., Gao J., Ferrington D. A., Biesiada H., Williams T. D. Squier T. C. (1999) Repair of oxidized calmodulin by methionine sulfoxide reductase restores ability to activate the plasma membrane Ca-ATPase. Biochemistry 38, 105 112.
240. Syme C. D., Blanch E. W., Holt C., Jakes R., Goedert M., Hecht L. Barron L. D. (2002) A Raman optical activity study of rheomorphism in caseins, synucleins and tau. New insight into the structure and behaviour of natively unfolded proteins. Eur. J. Biochem. 269, 148 156.
241. Takahashi M., Kanuka H., Fujiwara H., Koyama A., Hasegawa M., Miura M. Iwatsubo T. (2003) Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci. Lett. 336, 155 158.
242. Takeda A., Mallory M., Sundsmo M., Honer W., Hansen L. Masliah E. (1998) Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am. J. Pathol. 152, 367 372.
243. Takeda A., Hashimoto M., Mallory M., Sundsumo M., Hansen L. Masliah E. (2000) C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathol. (Berl.) 99, 296 304.
244. Talpade D. J., Greene J. G., Higgins D. S. Jr. Greenamyre J. T. (2000) In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone. J. Neurochem. 75, 2611 2621.
245. Tamamizu-Kato S., Kosaraju M. G., Kato H., Raussens V., Ruysschaert J. M. Narayanaswami V. (2006) Calcium-triggered membrane interaction of the alpha-synuclein acidic tail. Biochemistry 45, 10947 10956.
246. Tanner C. M. (1989) The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci. 12, 49 54.
247. Tanner C. M. Aston D. A. (2000) Epidemiology of Parkinson's disease and akinetic syndromes. Curr. Opin. Neurol. 13, 427 430.
248. Tanner C. M., Chen B., Wang W., Peng M., Liu Z., Liang X., Kao L. C., Gilley D. W., Goetz C. G. Schoenberg B. S. (1989) Environmental factors and Parkinson's disease: a case-control study in China. Neurology 39, 660 664.
249. Tofaris G. K. Spillantini M. G. (2005) Alpha-synuclein dysfunction in Lewy body diseases. Mov. Disord. 20 (Suppl. 12 S37 S44.
250. Tompa P. (2002) Intrinsically unstructured proteins. Trends Biochem. Sci. 27, 527 533.
251. Tompa P. (2005) The interplay between structure and function in intrinsically unstructured proteins. FEBS Lett. 579, 3346 3354.
252. Tompa P. Csermely P. (2004) The role of structural disorder in the function of RNA and protein chaperones. FASEB J. 18, 1169 1175.
253. Tompa P., Szasz C. Buday L. (2005) Structural disorder throws new light on moonlighting. Trends Biochem. Sci. 30, 484 489.
254. Trojanowski J. Q. Lee V. M. (2003) Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses. Ann. NY Acad. Sci. 991, 107 110.
255. Trojanowski J. Q., Goedert M., Iwatsubo T. Lee V. M. (1998) Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ. 5, 832 837.
256. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D. A., Kondo J., Ihara Y. Saitoh T. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 11282 11286.
257. Uitti R. J., Snow B. J., Shinotoh H., Vingerhoets F. J., Hayward M., Hashimoto S., Richmond J., Markey S. P., Markey C. J. Calne D. B. (1994) Parkinsonism induced by solvent abuse. Ann. Neurol. 35, 616 619.
258. Ulmer T. S., Bax A., Cole N. B. Nussbaum R. L. (2005) Structure and dynamics of micelle-bound human alpha-synuclein. J. Biol. Chem. 280, 9595 9603.
259. Uversky V. N. (2002a) Natively unfolded proteins: a point where biology waits for physics. Protein Sci. 11, 739 756.
260. Uversky V. N. (2002b) What does it mean to be natively unfolded? Eur. J. Biochem. 269, 2 12.
261. Uversky V. N. (2003) A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn. 21, 211 234.
262. Uversky V. N. (2004) Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res. 318, 225 241.
263. Uversky V. N., Gillespie J. R. Fink A. L. (2000) Why are 'natively unfolded' proteins unstructured under physiologic conditions? Proteins 41, 415 427.
264. Uversky V. N., Li J. Fink A. L. (2001a) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276, 10737 10744.
265. Uversky V. N., Li J. Fink A. L. (2001b) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276, 44284 44296.
266. Uversky V. N., Li J. Fink A. L. (2001c) Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett. 500, 105 108.
267. Uversky V. N., Li J. Fink A. L. (2001d) Trimethylamine-N-oxide-induced folding of alpha-synuclein. FEBS Lett. 509, 31 35.
268. Uversky V. N., Lee H. J., Li J., Fink A. L. Lee S. J. (2001e) Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J. Biol. Chem. 276, 43495 43498.
269. Uversky V. N., Li J., Bower K. Fink A. L. (2002a) Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease. Neurotoxicology 23, 527 536.
270. Uversky V. N., E M. C., Bower K. S., Li J. Fink A. L. (2002b) Accelerated alpha-synuclein fibrillation in crowded milieu. FEBS Lett. 515, 99 103.
271. Uversky V. N., Yamin G., Souillac P. O., Goers J., Glaser C. B. Fink A. L. (2002c) Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett. 517, 239 244.
272. Uversky V. N., Li J., Souillac P., Millett I. S., Doniach S., Jakes R., Goedert M. Fink A. L. (2002d) Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J. Biol. Chem. 277, 11970 11978.
273. Uversky V. N., Oldfield C. J. Dunker A. K. (2005a) Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling. J. Mol. Recognit. 18, 343 384.
274. Uversky V. N., Yamin G., Munishkina L. A., Karymov M. A., Millett I. S., Doniach S., Lyubchenko Y. L. Fink A. L. (2005b) Effects of nitration on the structure and aggregation of alpha-synuclein. Brain Res. Mol. Brain Res. 134, 84 102.
275. Vanacore N., Nappo A., Gentile M. et al. (2002) Evaluation of risk of Parkinson's disease in a cohort of licensed pesticide users. Neurol. Sci. 23 (Suppl. 2 S119 S120.
276. Vila M. Przedborski S. (2004) Genetic clues to the pathogenesis of Parkinson's disease. Nat. Med. 10 (Suppl. S58 S62.
277. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M. Przedborski S. (2000) Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74, 721 729.
278. Vogt W. (1995) Oxidation of methionyl residues in proteins: tools, targets, and reversal. Free Radic. Biol. Med. 18, 93 105.
279. Volles M. J. Lansbury P. T. Jr. (2002) Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595 4602.
280. Wakabayashi K., Matsumoto K., Takayama K., Yoshimoto M. Takahashi H. (1997) NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett. 239, 45 48.
281. Wakabayashi K., Yoshimoto M., Tsuji S. Takahashi H. (1998) Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 249, 180 182.
282. Walker R. H., Brin M. F., Sandu D., Gujjari P., Hof P. R., Warren Olanow C. Shashidharan P. (2001) Distribution and immunohistochemical characterization of torsinA immunoreactivity in rat brain. Brain Res. 900, 348 354.
283. Weinreb P. H., Zhen W., Poon A. W., Conway K. A. Lansbury P. T. Jr. (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709 13715.
284. Willingham S., Outeiro T. F., DeVit M. J., Lindquist S. L. Muchowski P. J. (2003) Yeast genes that enhance the toxicity of a mutant Huntingtin fragment or alpha-synuclein. Science 302, 1769 1772.
285. Wolozin B. Golts N. (2002) Iron and Parkinson's disease. Neuroscientist 8, 22 32.
286. Wright P. E. Dyson H. J. (1999) Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J. Mol. Biol. 293, 321 331.
287. Wu J. A., Attele A. S., Zhang L. Yuan C. S. (2001) Anti-HIV activity of medicinal herbs: usage and potential development. Am. J. Chin. Med. 29, 69 81.
288. Xu J., Kao S. Y., Lee F. J., Song W., Jin L. W. Yankner B. A. (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8, 600 606.
289. Yamin G., Uversky V. N. Fink A. L. (2003a) Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett. 542, 147 152.
290. Yamin G., Glaser C. B., Uversky V. N. Fink A. L. (2003b) Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. J. Biol. Chem. 278, 27630 27635.
291. Yamin G., Munishkina L. A., Karymov M. A., Lyubchenko Y. L., Uversky V. N. Fink A. L. (2005) Forcing non-amyloidogenic β-synuclein to fibrillate. Biochemistry 44, 9096 9107.
292. Yancey P. H., Clark M. E., Hand S. C., Bowlus R. D. Somero G. N. (1982) Living with water stress: evolution of osmolyte systems. Science 217, 1214 1222.
293. Yang Z. R., Thomson R., McNeil P. Esnouf R. M. (2005) RONN: the bio-basis function neural network technique applied to the detection of natively disordered regions in proteins. Bioinformatics 21, 3369 3376.
294. Yasui M., Kihira T. Ota K. (1992) Calcium, magnesium and aluminum concentrations in Parkinson's disease. Neurotoxicology 13, 593 600.
295. Zarranz J. J., Alegre J., Gomez-Esteban J. C. et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164 173.
296. Zhou W., Hurlbert M. S., Schaack J., Prasad K. N. Freed C. R. (2000) Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 866, 33 43.
297. Zhu M. Fink A. L. (2003) Lipid binding inhibits alpha-synuclein fibril formation. J. Biol. Chem. 278, 16873 16877.
298. Zhu M., Li J. Fink A. L. (2003) The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J. Biol. Chem. 278, 40186 40197.
299. Zhu M., Rajamani S., Kaylor J., Han S., Zhou F. Fink A. L. (2004) The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J. Biol. Chem. 279, 26846 26857.
300. Zhu M., Qin Z. J., Hu D., Munishkina L. A. Fink A. L. (2006) Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. Biochemistry 45, 8135 8142.
301. Zimmerman S. B. Trach S. O. (1991) Estimation of macromolecule concentrations and excluded volume effects for the cytoplasm of Escherichia coli. J. Mol. Biol. 222, 599 620.